Standout Papers

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With R... 2012 2026 2016 2021 832
  1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (2012)
    Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology
  2. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy (2021)
    Alexander Bagaev, Nikita Kotlov et al. Cancer Cell

Immediate Impact

1 by Nobel laureates 28 from Science/Nature 77 standout
Sub-graph 1 of 21

Citing Papers

A vision–language foundation model for precision oncology
2025 StandoutNature
Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
11 intermediate papers

Works of Nathan Fowler being referenced

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study
2013
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
2012 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Nathan Fowler 3511 2749 2424 264 5.6k
Sonali M. Smith 4064 3254 2274 262 6.6k
Jan Delabie 4574 3108 1877 197 6.8k
Lisa M. Rimsza 3417 2577 1516 198 6.0k
Marek Trněný 4806 3916 2278 321 6.7k
Felipe Samaniego 3069 3126 1467 217 7.2k
Kristie A. Blum 4354 2512 3806 206 6.5k
Yasuhiro Oki 3049 2241 1688 206 6.1k
Kieron Dunleavy 3450 2610 1561 145 5.4k
Ann S. LaCasce 4800 3336 2230 204 7.4k
Lorenz Trümper 3812 3200 2007 197 7.3k

All Works

Loading papers...

Rankless by CCL
2026